Revised forecast
Fiscal year ending March 2027 · Second quarter (interim period)Previous forecast published 13 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Takara Shuzo has revised its sales forecast downward because demand brought forward was below expectations, but has revised its operating profit forecast upward due to the efficient use of selling, general and administrative expenses and other factors. The Takara Shuzo International Group has revised its forecast upward due to higher overseas sales, higher gross profit resulting from price revisions, reciprocal tariff refunds and foreign exchange effects. Although the Takara Bio Group expects lower sales in its reagents business and a downside from its product mix, operating loss is expected to narrow as selling, general and administrative expenses decline.
| Item | Details |
|---|---|
| Net Sales | ¥205,000 million → ¥210,870 million（+2.9%） |
| Operating profit | ¥8,800 million → ¥13,112 million（+49.0%） |
| Ordinary income | ¥7,800 million → ¥12,764 million（+63.6%） |
| Profit attributable to owners of the parent | ¥5,900 million → ¥11,682 million（+98.0%） |
| Net income per share | ¥30.59 → ¥60.87 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Second quarter (interim period) |
| Publication date of previous forecast | 13 May 2026 |
| Previous-period results | Net sales: ¥186,556 million; operating profit: ¥7,786 million; ordinary profit: ¥7,386 million; interim net income attributable to owners of the parent: ¥5,695 million; interim net income per share: ¥29.40 (second quarter of the fiscal year ending March 2026) |
| Reason for the revision | Takara Shuzo has revised its sales forecast downward because demand brought forward was below expectations, but has revised its operating profit forecast upward due to the efficient use of selling, general and administrative expenses and other factors. The Takara Shuzo International Group has revised its forecast upward due to higher overseas sales, higher gross profit resulting from price revisions, reciprocal tariff refunds and foreign exchange effects. Although the Takara Bio Group expects lower sales in its reagents business and a downside from its product mix, operating loss is expected to narrow as selling, general and administrative expenses decline. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Takara Shuzo expects net sales to decline as demand brought forward ahead of the price revisions was below expectations, while operating profit is expected to exceed the forecast due to the efficient use of selling, general and administrative expenses. The Takara Shuzo International Group expects profit to increase due to higher overseas sales, higher gross profit resulting from price revisions, reciprocal tariff refunds and foreign exchange effects. Although the Takara Bio Group expects lower sales in its reagents business and lower gross profit due to its product mix, operating loss is expected to narrow as selling, general and administrative expenses related to Spatial products decline.